Melanotan I Has an Unusual Research History
Most research peptides remain laboratory molecules.
Melanotan I is different.
Originally studied as [Nle4,D-Phe7]-α-MSH, Melanotan-I became closely associated with the pharmaceutical molecule afamelanotide.
Today, afamelanotide is the active substance in the FDA-approved prescription product SCENESSE, used for a specific indication in adults with erythropoietic protoporphyria.
That history makes Melanotan I / MT-1 scientifically important.
It also creates a sourcing problem:
A research vial labeled “Melanotan I” should not automatically be treated as the approved pharmaceutical SCENESSE.
What Is Melanotan I?
Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH).
Its structural modifications make it more resistant to degradation than native α-MSH, which is one reason it has been studied extensively in melanocortin and pigmentation research. High-ranking research suppliers commonly describe MT-1 as a melanocortin-pathway or MC1R research peptide.
Relevant research areas include:
melanocortin receptor signaling, MC1R biology, melanogenesis, eumelanin production and pigmentation pathways.
Human Data Exist—but Context Matters
Unlike many research peptides, Melanotan-I has published human pharmacology data.
An early human study reported measurable skin pigmentation after Melanotan-I exposure and noted occasional gastrointestinal upset and facial flushing.
Additional research documented increased eumelanin expression and tanning responses in human skin.
These findings help explain why search terms such as Melanotan I peptide, MT-1 peptide and alpha-MSH analog remain popular.
But historical research does not mean independently supplied research material is an approved tanning treatment.
Afamelanotide Approval Does Not Make Every MT-1 Product a Drug
FDA approved SCENESSE (afamelanotide) in 2019 for increasing pain-free light exposure in adults with EPP who have a history of phototoxic reactions.
That approval applies to a specific regulated pharmaceutical product.
Research-grade Melanotan I / Afamelanotide research analog supplied by an independent manufacturer is not automatically:
FDA approved, pharmaceutically equivalent, clinically interchangeable or manufactured to the same finished-drug specifications.
For B2B buyers, this distinction is essential.
The molecule name identifies a research target. It does not establish pharmaceutical equivalence.
Positive and Negative MT-1 Reviews Need Caution
Recent community discussions contain positive anecdotes describing visible pigmentation and fewer subjective side effects than users associate with MT-2.
However, community evidence has major limitations.
Products are rarely independently authenticated, users often compare different compounds, and uncontrolled experiences cannot establish safety or efficacy.
Published literature has also raised concerns about the unregulated use of untested synthetic α-MSH analogues.
For laboratories, this leads to a better question:
Can the material itself be verified?
What Should a Melanotan I Buyer Verify?
Professional buyers evaluating a Melanotan I supplier should confirm:
Molecular identity — Does the material correspond to the stated MT-1 structure?
HPLC purity — Is the purity result linked to the supplied lot?
Batch COA — Does the Certificate of Analysis match the shipment?
Storage requirements — Are stability and light-protection conditions defined?
Traceability — Can the material be linked to its QC documentation?
SUNONE currently specifies storage at 2–8°C protected from light and makes COA and purity documentation available for its research product.
SUNONE Melanotan I Research Peptide
SUNONE supplies Melanotan I / MT-1 for qualified laboratory and manufacturing research.
Current specifications include:
CAS: 75921-69-6
Formula: C78H111N21O19
Molecular Weight: 1646.9 g/mol
Purity: ≥99%, HPLC
Form: Lyophilized Powder
B2B Sizes: 5 mg and 10 mg
Documentation: COA, SDS and Specification Sheet.
View SUNONE Melanotan I Specifications :
Looking for a Melanotan I Supplier with COA?
For biotechnology companies, peptide laboratories and research distributors, the important sourcing question is not simply:
“Is this MT-1?”
The stronger question is:
“Can the supplier document the identity, purity and batch characteristics of the Melanotan I being supplied?”
If your organization is sourcing Melanotan I peptide, MT-1, alpha-MSH analog, melanocortin research peptide or related pigmentation-research materials, SUNONE can provide current specifications, batch documentation, MOQ, packaging and B2B quotation information.
Conclusion
Melanotan I has a stronger pharmaceutical history than many research peptides.
That makes precise terminology more important—not less.
Melanotan I, afamelanotide and SCENESSE are related scientific entities, but a research product should never be assumed equivalent to the approved finished medicine simply because the names overlap.
For professional research procurement:
verify the identity, verify the HPLC purity, verify the storage specification and verify the batch-specific COA.
The familiar name may attract the search.
The documentation should earn the inquiry.
This content is provided for scientific and educational purposes only. SUNONE research peptide is for qualified labrtorynt, diagnois, druc tor mmatct or veteimant, use.research only, Not for human consumption, clinical treame. Purchasers are responsible for complying with applicable laws and regulations in their jurisdiction.
Leave a Reply